394 related articles for article (PubMed ID: 34417327)
1. Tuberous Sclerosis Complex (TSC) Inactivation Increases Neuronal Network Activity by Enhancing Ca
Hisatsune C; Shimada T; Miyamoto A; Lee A; Yamagata K
J Neurosci; 2021 Sep; 41(39):8134-8149. PubMed ID: 34417327
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological intervention to restore connectivity deficits of neuronal networks derived from ASD patient iPSC with a TSC2 mutation.
Alsaqati M; Heine VM; Harwood AJ
Mol Autism; 2020 Oct; 11(1):80. PubMed ID: 33076974
[TBL] [Abstract][Full Text] [Related]
3. Biallelic Mutations in
Winden KD; Sundberg M; Yang C; Wafa SMA; Dwyer S; Chen PF; Buttermore ED; Sahin M
J Neurosci; 2019 Nov; 39(47):9294-9305. PubMed ID: 31591157
[TBL] [Abstract][Full Text] [Related]
4. The role of TSC1 and TSC2 proteins in neuronal axons.
Karalis V; Wood D; Teaney NA; Sahin M
Mol Psychiatry; 2024 Apr; 29(4):1165-1178. PubMed ID: 38212374
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
[TBL] [Abstract][Full Text] [Related]
6.
He J; Zhou W; Shi J; Lin J; Zhang B; Sun Z
Genet Test Mol Biomarkers; 2020 Jan; 24(1):1-5. PubMed ID: 31855466
[No Abstract] [Full Text] [Related]
7. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
8. Tuberous sclerosis: a review of the past, present, and future.
Uysal SP; Şahin M
Turk J Med Sci; 2020 Nov; 50(SI-2):1665-1676. PubMed ID: 32222129
[TBL] [Abstract][Full Text] [Related]
9. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
[TBL] [Abstract][Full Text] [Related]
10. RHOA signaling defects result in impaired axon guidance in iPSC-derived neurons from patients with tuberous sclerosis complex.
Catlett TS; Onesto MM; McCann AJ; Rempel SK; Glass J; Franz DN; Gómez TM
Nat Commun; 2021 May; 12(1):2589. PubMed ID: 33972524
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
12. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
13. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
Mizuguchi M; Ohsawa M; Kashii H; Sato A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
[TBL] [Abstract][Full Text] [Related]
14. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1.
Di Nardo A; Wertz MH; Kwiatkowski E; Tsai PT; Leech JD; Greene-Colozzi E; Goto J; Dilsiz P; Talos DM; Clish CB; Kwiatkowski DJ; Sahin M
Hum Mol Genet; 2014 Jul; 23(14):3865-74. PubMed ID: 24599401
[TBL] [Abstract][Full Text] [Related]
15. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V
Mol Autism; 2020; 11(1):2. PubMed ID: 31921404
[TBL] [Abstract][Full Text] [Related]
16. Astroglial calcium signaling and homeostasis in tuberous sclerosis complex.
Romagnolo A; Dematteis G; Scheper M; Luinenburg MJ; Mühlebner A; Van Hecke W; Manfredi M; De Giorgis V; Reano S; Filigheddu N; Bortolotto V; Tapella L; Anink JJ; François L; Dedeurwaerdere S; Mills JD; Genazzani AA; Lim D; Aronica E
Acta Neuropathol; 2024 Feb; 147(1):48. PubMed ID: 38418708
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress.
Zimmer TS; Korotkov A; Zwakenberg S; Jansen FE; Zwartkruis FJT; Rensing NR; Wong M; Mühlebner A; van Vliet EA; Aronica E; Mills JD
Brain Pathol; 2021 Sep; 31(5):e12949. PubMed ID: 33786950
[TBL] [Abstract][Full Text] [Related]
18. The genomic landscape of tuberous sclerosis complex.
Martin KR; Zhou W; Bowman MJ; Shih J; Au KS; Dittenhafer-Reed KE; Sisson KA; Koeman J; Weisenberger DJ; Cottingham SL; DeRoos ST; Devinsky O; Winn ME; Cherniack AD; Shen H; Northrup H; Krueger DA; MacKeigan JP
Nat Commun; 2017 Jun; 8():15816. PubMed ID: 28643795
[TBL] [Abstract][Full Text] [Related]
19. High glucose concentrations mask cellular phenotypes in a stem cell model of tuberous sclerosis complex.
Rocktäschel P; Sen A; Cader MZ
Epilepsy Behav; 2019 Dec; 101(Pt B):106581. PubMed ID: 31761686
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]